US Patent 8,153,661: Claim Scope, Expiration, Litigation Risk, and Bupivacaine Patent Landscape

US Patent No. 8,153,661 protects a method of providing sustained local anesthesia using a narrowly defined SAIB-based bupivacaine formulation. The independent claim requires approximately 66% sucrose acetate isobutyrate, 12% bupivacaine, and 22% benzyl alcohol by weight, with release lasting at least 24 hours. The patent is directed to use of the formulation, not to a standalone composition claim.

The principal commercial relevance is the relationship between the claimed formulation and DURECT Corporation's SABER technology and POSIMIR development program. The patent does not automatically block every long-acting bupivacaine product. Products using liposomal carriers, different excipients, different concentrations, or different release profiles may fall outside literal claim scope.

What does US Patent 8,153,661 cover?

The patent covers a treatment method requiring administration of a composition with three required formulation components:

Required component	Claimed amount
Sucrose acetate isobutyrate, or SAIB	About 66% by weight
Bupivacaine	About 12% by weight
Benzyl alcohol, or BA	About 22% by weight
Release requirement	At least 24 hours of sustained local anesthesia

Claim 1 is the controlling claim. It requires all of the following:

A subject receives the composition.
The composition contains SAIB, bupivacaine, and benzyl alcohol.
The approximate weight proportions are satisfied.
Bupivacaine is released for at least 24 hours.
The amount released is sufficient to provide sustained local anesthesia.

The claim uses the transitional term "comprising." That term generally makes the claim open-ended. Additional excipients or formulation components may therefore be present, provided the accused formulation still contains the required components and satisfies the remaining limitations.

The patent claim is a method claim. It does not, based on the supplied claims, independently claim:

SAIB as a general drug-delivery platform;
every SAIB-bupivacaine formulation;
every sustained-release bupivacaine product;
a composition sold without a method of use;
a manufacturing process for making the formulation; or
a particular commercial product by brand name.

How do the nine claims differ?

Claim	Scope
1	Broadest method claim; requires the 66/12/22 SAIB-bupivacaine-BA formulation and at least 24-hour release
2	Limits administration to a surgical wound
3	Requires administration into or adjacent to the surgical wound
4	Requires administration by pouring
5	Limits the patient and procedure to human inguinal hernia repair or appendectomy
6	Limits use to treatment of postoperative pain
7	Requires bupivacaine in free-base form
8	Requires sustained local anesthesia for at least approximately 48 hours
9	Requires sustained local anesthesia for at least approximately 72 hours

Claims 2 through 9 depend from claim 1, directly or indirectly. Each dependent claim incorporates every limitation of claim 1 and adds another restriction.

Claim 1 is commercially more important than the dependent claims because it covers the widest patient population and does not require a surgical wound, a particular operation, pouring, postoperative pain, or free-base bupivacaine. Claims 5 and 9 may be easier to design around because they contain more specific clinical or duration requirements.

What formulation is protected by US 8,153,661?

The formulation is an SAIB-based depot or in situ sustained-release system. SAIB functions as the principal liquid carrier. Benzyl alcohol is included as a solvent or formulation component, while bupivacaine is the local anesthetic.

The central formulation limitation is the approximate 66:12:22 weight relationship:

66 parts SAIB;
12 parts bupivacaine;
22 parts benzyl alcohol.

The claims do not specify an explicit numerical tolerance for "about." The scope of that term would ordinarily depend on the patent specification, examples, prosecution history, technical meaning in the field, and the circumstances of an infringement dispute. A court would not necessarily treat "about 66%" as a fixed plus-or-minus percentage.

A formulation containing 65% SAIB, 12% bupivacaine, and 23% benzyl alcohol may present a different analysis from a formulation containing 45% SAIB, 20% bupivacaine, and 35% benzyl alcohol. The closer the formulation is to the disclosed and claimed proportions, the greater the literal-infringement and doctrine-of-equivalents risk.

Does claim 1 require exactly three ingredients?

No. "Comprising" generally permits additional ingredients. The claim still requires the three named components in the claimed approximate proportions. An added antioxidant, buffer, stabilizer, viscosity modifier, or other excipient would not necessarily avoid the claim.

The additional component could matter if it changes the weight calculation, prevents the composition from satisfying the approximate percentages, or materially alters the release behavior.

Does claim 7 cover bupivacaine hydrochloride?

Claim 7 specifically requires free-base bupivacaine. A formulation using bupivacaine hydrochloride may fall outside claim 7. That does not automatically avoid claim 1, however, because claim 1 does not expressly require the free-base form. The chemical form would be relevant to claim construction, infringement, and validity analysis.

What is the required release profile?

Claim 1 requires release for "a period of at least 24 hours in an amount sufficient to provide sustained local anesthesia." Claims 8 and 9 extend the express duration requirement to approximately 48 and 72 hours, respectively.

This limitation has two components:

Duration: release must continue for at least the stated period.
Functional effect: the released bupivacaine must be sufficient to provide sustained local anesthesia.

A formulation that releases trace quantities for 24 hours may not satisfy the claim if it does not provide sufficient anesthesia. Conversely, a formulation that provides analgesia for 24 hours through a different mechanism may not meet the claim if it does not release bupivacaine in the claimed manner.

The release limitation creates evidentiary issues in litigation. Relevant evidence could include:

in vitro release testing;
in vivo pharmacokinetic data;
tissue concentrations;
duration of sensory blockade;
formulation stability;
clinical analgesic endpoints; and
product labeling or technical documentation.

What surgical procedures are covered?

The claims cover a broad set of administration scenarios.

Claim 1 has no express surgical limitation. Claims 2 through 4 introduce a surgical-wound setting:

administration to a surgical wound;
administration into or adjacent to the wound; and
administration by pouring.

Claim 5 narrows the use to human surgical inguinal hernia repair or appendectomy. Claim 6 covers postoperative pain treatment without limiting the procedure to those named in claim 5.

The use of "or" in claim 5 means the claim reaches either listed procedure. A product used in hernia repair may satisfy claim 5 even if it is not used in appendectomy, assuming every limitation of claim 1 is also met.

When does US Patent 8,153,661 lose exclusivity?

The patent issued on April 10, 2012. Its effective expiration date depends on the patent family's earliest effective nonprovisional filing or priority date, patent-term adjustment, patent-term extension, terminal disclaimers, and any applicable regulatory extension.

The patent's nominal term is generally calculated under the 20-year patent-term framework. A reliable expiration analysis therefore must distinguish:

Date type	Significance
Earliest effective filing or priority date	Determines the base patent term
Nonprovisional filing date	May control where priority is unavailable or ineffective
Issue date	Generally does not control modern patent term
Patent-term adjustment	Can extend the term for qualifying USPTO delays
Patent-term extension	May extend term for qualifying regulatory review
Terminal disclaimer	May shorten the enforceable term
Reexamination or post-grant proceedings	May alter claim scope but ordinarily do not create a new term

The supplied claims do not contain the prosecution data needed to calculate a legally definitive expiration date. The patent record and USPTO Patent Center remain controlling for the term calculation. The relevant commercial question is whether any patent-term adjustment or regulatory extension moved the effective expiration beyond the nominal 20-year date.

What is the Orange Book status of US 8,153,661?

A patent number alone does not establish Orange Book listing status. FDA Orange Book listing depends on the approved drug application, the product sponsor's submission, and FDA acceptance of the patent information.

For a small-molecule product, an Orange Book-listed patent can create a statutory notice and litigation framework for an abbreviated new drug application. The relevant questions are:

whether the patent is listed against an approved NDA;
whether the listing covers the approved formulation, method of use, or drug substance;
whether the listed claims remain enforceable;
whether a generic applicant certifies Paragraph IV; and
whether the NDA holder or patent owner brings an action within the statutory period.

The claims supplied are method claims directed to sustained local anesthesia. Their Orange Book relevance would depend on whether the patented method corresponds to an FDA-approved indication or use code. A patent covering a method not reflected in the approved labeling may not provide the same listing or litigation position as a patent covering the approved use.

FDA's Orange Book and the applicable NDA patent-listing record are the authoritative sources for current listing status. [2]

What Paragraph IV risks exist?

A generic applicant could make a Paragraph IV certification against an Orange Book-listed patent by asserting that the patent is invalid, unenforceable, or not infringed. The principal noninfringement positions against this patent would include:

the formulation does not contain approximately 66% SAIB;
bupivacaine is present at a materially different concentration;
benzyl alcohol is outside the claimed range;
the product does not release bupivacaine for at least 24 hours;
the release does not provide sustained local anesthesia;
the proposed use does not practice the claimed method; or
the product uses a different bupivacaine form or delivery mechanism.

Potential invalidity arguments would include:

anticipation by an earlier SAIB-bupivacaine formulation;
obviousness based on prior sustained-release local-anesthetic technology;
lack of written description for the claimed formulation and functional release profile;
lack of enablement across the scope of the "about" ranges and release requirement; and
indefiniteness relating to "about," "sufficient," or "sustained local anesthesia."

The exact 66/12/22 formulation may strengthen anticipation and obviousness defenses if closely matched prior art exists. It may strengthen patent-owner arguments if the formulation and clinical performance were difficult to predict from the prior art.

How strong is the patent estate?

The supplied claims indicate a focused patent position rather than a broad platform estate.

Strengths

The patent has several commercially useful features:

It claims a defined formulation rather than only a general concept.
It combines composition limitations with a therapeutic release requirement.
It covers administration to a subject, which can support direct method-of-use infringement.
Claim 1 is not limited to one surgical procedure.
The dependent claims address surgical wounds, pouring, free-base bupivacaine, and 48- or 72-hour duration.

Weaknesses

The claim scope also has material limitations:

The three component percentages are narrow.
The claims do not expressly cover all SAIB carriers or all bupivacaine concentrations.
The patent does not appear, from the supplied claims, to include composition or manufacturing claims.
Functional terms such as "sufficient" and "sustained local anesthesia" may create proof and indefiniteness disputes.
Claim 5 is limited to two named procedures.
A competitor using liposomal delivery, a polymeric depot, or a different solvent system may avoid literal infringement.

Patent strength therefore depends heavily on the patent family, specification, prosecution history, cited prior art, and any related continuation patents. The nine claims alone do not establish the strength of the broader patent portfolio.

How does this patent compare with Exparel and Zynrelef?

US 8,153,661 should be analyzed against competing long-acting local-anesthetic products, but the products use materially different delivery approaches.

Product or technology	Active components	Delivery approach	Relationship to US 8,153,661
SAIB-bupivacaine technology	Bupivacaine, SAIB, benzyl alcohol	Liquid depot or in situ sustained-release system	Directly relevant
Exparel	Bupivacaine liposome injectable suspension	Multivesicular liposomal delivery	Generally different formulation architecture
Zynrelef	Bupivacaine and meloxicam	Extended-release solution applied to a surgical site	Potentially competing product; formulation is materially different
Conventional bupivacaine injection	Bupivacaine	Immediate or relatively short-duration injection	Usually lacks the claimed sustained-release formulation
Continuous infusion systems	Bupivacaine delivered through a catheter or pump	Mechanical controlled infusion	Typically different from the claimed SAIB composition

Exparel and Zynrelef may compete clinically for postoperative pain management without practicing the specific SAIB-bupivacaine-BA formulation claim. Their patent estates must be evaluated separately. A competing product can be commercially substitutable without infringing this patent.

No biosimilar pathway applies to bupivacaine products. Bupivacaine is a chemically synthesized small molecule, so the principal generic pathway is an ANDA, not a biosimilar application under the Public Health Service Act.

What litigation and settlement issues matter?

The main litigation risks concern formulation testing and product labeling.

A patent owner could pursue:

direct infringement against a party administering the formulation;
induced infringement against a manufacturer whose labeling instructs the claimed use;
contributory infringement where the formulation has limited noninfringing uses;
an injunction against launch;
damages based on lost sales or a reasonable royalty; and
an action following a Paragraph IV certification.

A generic or competing sponsor would likely focus on noninfringement through a formulation and use design-around. The most practical design-around options are:

Replace SAIB with a liposomal, polymeric, or alternative depot carrier.
Alter the SAIB, bupivacaine, or benzyl-alcohol proportions beyond the interpreted "about" range.
Use a different chemical form of bupivacaine.
Avoid the claimed administration method.
Produce a release profile that does not provide the claimed sustained anesthesia.
Seek approval for a use not covered by any listed method claim.

No settlement terms, litigation outcome, or enforceability ruling can be established from the claims alone. Those issues require the docket, prosecution record, and any Orange Book certification history.

What geographic coverage does the patent provide?

US 8,153,661 provides rights only in the United States. Foreign counterparts, if any, require separate analysis by jurisdiction. Patent rights may differ across:

Europe;
Japan;
Canada;
Australia;
China;
South Korea; and
other national or regional patent offices.

A US design-around does not necessarily avoid corresponding foreign claims. Conversely, expiration, abandonment, claim amendments, or opposition proceedings in a foreign jurisdiction may create freedom to operate that is unavailable in the United States.

What manufacturing and intellectual-property barriers remain?

The patent is only one potential barrier. Commercial entry may also depend on:

formulation know-how for maintaining a homogeneous SAIB depot;
control of bupivacaine loading and precipitation;
benzyl alcohol compatibility;
sterilization and container-closure performance;
syringe or vial materials;
release testing methods;
scale-up reproducibility;
manufacturing process patents;
trade secrets;
FDA product-specific guidance;
clinical bridging requirements; and
patent rights covering approved indications or delivery devices.

A manufacturer can avoid literal infringement of US 8,153,661 and still face other patent or regulatory barriers. Conversely, the existence of this patent does not itself establish that the claimed formulation can be commercialized successfully or that it has FDA approval.

Key Takeaways

US 8,153,661 is a method patent centered on a 66% SAIB, 12% bupivacaine, and 22% benzyl alcohol formulation.
Claim 1 requires at least 24 hours of bupivacaine release sufficient to provide sustained local anesthesia.
The patent does not, based on the supplied claims, cover every sustained-release bupivacaine product.
Claims 2 through 6 focus on surgical wounds, pouring, hernia repair, appendectomy, and postoperative pain.
Claim 7 narrows the scope to free-base bupivacaine.
Claims 8 and 9 require approximately 48- and 72-hour anesthesia, respectively.
Literal infringement will likely turn on formulation percentages, chemical form, administration instructions, and release data.
Exparel and Zynrelef compete in the same broad clinical market but use materially different delivery systems.
Bupivacaine generics proceed through the ANDA pathway, not the biosimilar pathway.
Orange Book listing, patent-term adjustment, regulatory extension, and related continuation patents are decisive to the current exclusivity position.
The practical design-around path is to change the carrier system, formulation ratio, bupivacaine form, or approved use.

FAQs

Does US 8,153,661 cover a bupivacaine liposome product?

Generally, not on the face of the supplied claims. The claims require an SAIB-based composition containing benzyl alcohol and approximately 12% bupivacaine. A liposomal product with a different composition would ordinarily present a different infringement analysis.

Can a product infringe if it contains 66% SAIB but no benzyl alcohol?

It would not literally satisfy claim 1 because benzyl alcohol is a required component. The patent owner's possible doctrine-of-equivalents position would depend on the technical role of benzyl alcohol and the prosecution history.

Does administering the formulation next to, rather than inside, a surgical wound matter?

Claim 3 expressly covers administration "into and/or adjacent to" the surgical wound. Administration adjacent to the wound can therefore satisfy that dependent claim if all claim 1 limitations are also met.

Is a 24-hour pharmacokinetic release profile enough to satisfy the patent?

Not necessarily. The claim requires release for at least 24 hours in an amount sufficient to provide sustained local anesthesia. Pharmacokinetic duration and clinically sufficient anesthesia are related but distinct issues.

Can a generic applicant avoid the patent by labeling only non-surgical pain indications?

Potentially, if the proposed product and labeling do not practice the claimed method. The analysis would still depend on the formulation, actual use, induced-infringement theory, Orange Book listing, and any additional patent claims in the relevant family.

References

United States Patent and Trademark Office. (2012). U.S. Patent No. 8,153,661, sustained-release local anesthetic method claims.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2021). POSIMIR prescribing information.
U.S. Food and Drug Administration. (2024). ANDA submissions: Patent certifications and approval requirements.
United States Patent and Trademark Office. (2024). Manual of Patent Examining Procedure, patent term adjustment and patent term extension provisions.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E537844	⤷ Start Trial
Australia	2005287175	⤷ Start Trial
Brazil	PI0515372	⤷ Start Trial
Canada	2581287	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,153,661

Summary for Patent: 8,153,661